Guardion Health Sciences Announces Filing of Certificate of Dissolution
30. Oktober 2024 17:37 ET
|
Guardion Health Sciences, Inc.
HOUSTON, TEXAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) today announced that it has filed a certificate of dissolution with the...
Guardion Health Sciences Announces Adoption of Plan of Dissolution and Liquidation; Appointment of Interim President and CEO
01. Oktober 2024 09:00 ET
|
Guardion Health Sciences, Inc.
Plan includes Voluntary Delisting of Common Stock from Nasdaq and Suspension of SEC Reporting Obligations HOUSTON, TEXAS, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq:...
Guardion Health Sciences Declares Cash Dividend of $5.00 Per Share of Common Stock
21. August 2024 16:05 ET
|
Guardion Health Sciences, Inc.
HOUSTON, TEXAS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) today announced that its Board of Directors declared a cash dividend in...
Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2024
13. August 2024 16:35 ET
|
Guardion Health Sciences, Inc.
Guardion Also Provides an Update to Stockholders of Significant Recent Developments HOUSTON, TEXAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or...
Guardion Health Sciences Announces Approval by Stockholders of Proposed Sale of Viactiv Business
23. Mai 2024 15:00 ET
|
Guardion Health Sciences, Inc.
Adjourns Special Meeting to May 31, 2024 in order to Solicit Additional Proxies in Support of its Plan of Liquidation and Dissolution HOUSTON, TEXAS, May 23, 2024 (GLOBE NEWSWIRE) -- Guardion...
Guardion Health Sciences Announces its Largest Stockholder Has Voted in Favor of Proposals to Sell the Viactiv Business and the Liquidation Plan at the Company’s Special Meeting of Stockholders to be held on May 23, 2024
21. Mai 2024 08:00 ET
|
Guardion Health Sciences, Inc.
Company Estimates the Aggregate Potential Liquidating Distributions to Range from approximately $9.00 to $11.00 per Share if Stockholders Vote to Approve the Sale of the Company’s Viactiv Business and...
Guardion Health Sciences Announces
13. Mai 2024 17:01 ET
|
Guardion Health Sciences, Inc.
-- Financial Results for the Three Months Ended March 31, 2024 -- Institutional Shareholder Services Issues Report Recommending that Institutional Stockholders Vote in Favor of All Proposals at...
Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023
29. März 2024 06:15 ET
|
Guardion Health Sciences, Inc.
Viactiv® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared to the Year Ended December 31, 2022 ...
Guardion Health Sciences Announces Entry into Definitive Agreement to Sell its Well-Known Viactiv® Brand and Business to Doctor’s Best Inc.
30. Januar 2024 18:13 ET
|
Guardion Health Sciences, Inc.
HOUSTON, TEXAS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) announced today that it has signed an equity purchase agreement to sell...
Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2023
13. November 2023 16:10 ET
|
Guardion Health Sciences, Inc.
Viactiv® Generated Net Revenues of Approximately $3.3 Million for the Three Months Ended September 30, 2023, an increase of 27% over the Three Months Ended September 30, 2022 HOUSTON, TEXAS, Nov. ...